中國科興生物尋求全球進行旗下新冠疫苗第三階段臨床測試
在美國上市的中國科興生物(Sinovac Biotech)主席尹衛東接受《彭博通訊社》訪問時稱,正與其他國家監管機構及世衛(WHO)討論,在全球新冠疫情擴散仍嚴重的地方進行旗下疫苗第三階段臨床測試。
科興生物是走在抗疫最前線的三家中國公司之一,全球有逾100種新冠疫苗正在開發中,但只有約十隻進入最關鍵人體試驗最後階段。公司拒直接指出計劃在哪些國家進行試驗,但尹氏暗示美國是理想地方。尹氏稱,美國有最成熟生科行業,最精細的監管框架,以及該國現時疫情最嚴重。
除了科興生物的候選疫苗外,中國科學家還有三種疫苗在臨床測試,一種是康希諾生物(06185.HK)與中國軍方合作開發的疫苗;另有由國藥集團旗下中國生物技術股份(CNBG)開發的兩種疫苗。另美國藥廠如強生及Moderna亦在進行疫苗臨床測試。
康希諾生物亦有計劃全球測試,上月在加拿大提交了進行人體臨床測試的申請。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.